Pfizer Inc PFE

$30.67 +0.15 (0.49%)

Valuation

Market cap
173,954,048,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.82
P/E (forward)
10.17
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
50,818,500
Avg volume
31,970,018
Day's range
$30.20 – $31.04
Shares out
5,699,674,000
Stochastic %K
80%
Beta
0.32
Analysts
Hold
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

KevinohWarsh Nov 3, 11:14 AM
$PFE do or die baby
0 replies
parcha Nov 3, 10:45 AM
https://www.cnbc.com/2026/11/02/tuesdays-big-stock-stories-whats-likely-to-move-the-market.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $PFE $DD Big earnings before the bell on ‘Squawk Box’ Pfizer is up 22% in three months. Shares hit a new high on Monday. DuPont is up 3% in three months. The stock is 10% from the February high
0 replies
GlobalTradersAcademy Nov 3, 6:44 AM
Something's going on under the surface in $PFE: off-exchange volume ran well above normal, about 1.6x. Price didn't move much, which is what you'd expect if somebody big is building or unwinding a position quietly. The options side leaned calls the same day. Size, timing and what the options tape did alongside it: https://globaltradersacademy.com/articles/dark-pool-activity-unusual-off-exchange-trading-in-pfizer-pfe?utm_source=stocktwits&utm_medium=social
0 replies
Diehard777 Nov 3, 5:17 AM 0 replies
Diehard777 Nov 3, 4:54 AM
$PFE After earnings call 📣📣📣📣📣📣📣📣📣📣📣📣📣
2 replies
jrh34 Nov 3, 3:51 AM
$PFE Soldier on towards $50/share.
1 replies
Techdamentals Nov 3, 3:21 AM
$PFE reports third-quarter earnings on Tuesday, November 3, 2026 before the open, which is also midterm election day. Analysts expect EPS (profit per share) of about $0.74 on revenue near $15.85B, and options pricing points to a move of about 5% either way. Every earnings report hands analysts new numbers, so a fair value range can shift four times a year. Here is the Techdamentals IV Calculator range. What is it worth? 👇 https://techdamentals.com/v/PFE?ref=st Educational, not advice.
0 replies
polishsmokestack Nov 3, 1:43 AM
$NVAX $PFE earnings in the morning. Will the #s be good? Will they mention matrix m? Pfe went feom 24 to 31 quick as well as most big pharma did as $$$ rotates out of tech.
1 replies